Allarity Therapeutics, Inc. (ALLR): R&D Expense
$6.60M
Year ended 2025-12-31
$5.52M
Trailing 12 months to 2026-06-30
-1.6%
3-year compound annual growth
+9.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.60M | +8.3% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $6.10M | -14.2% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $7.10M | +2.5% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $6.93M | -51.2% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $14.20M | +236.6% | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | $4.22M | n/a | 2022-05-17, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $6.60M | +8.3% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $121.1K | -32.5% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $1.96M | -12.5% |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $11.7K | -92.4% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
Compare ALLR, HIND, PVCT, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗